 |
 |

Pain Management in Patients With Osteoarthritis
 |
 |
| Since this article does not have an abstract, we have provided the first 118 words of the full text and any section headings. |
|
 |
 |
To the Editor: In his Clinical Crossroads article about a 57-year-old man with arthritis, Dr Lonner1 stated that cyclooxygenase-2 (COX-2) selective inhibitors are as effective as nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), but may have "decreased toxicity on non-target tissues such as the gastric mucosa, although at 15 to 20 times the cost." In support of this assertion he cites data from the Celecoxib Long-term Arthritis Safety Study (CLASS).2 In fact, however, a later analysis revealed that 12 months of celecoxib was no safer than other NSAIDs, and the US Food and Drug Administration disagreed with the manufacturer's claim that celecoxib was safer.3
Thomas E. Finucane, MD
Division of Geriatric Medicine and Gerontology Johns Hopkins Geriatrics Center Baltimore, Md
1. Lonner JH. A 57-year-old man with osteoarthritis of the knee. JAMA. 2003;289:1016-1025.
FREE FULL TEXT
2. Silverstein FE, Faich G, Goldstein JL, et al, Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000;284:1247-1255.
FREE FULL TEXT
3. Witter J. Celebrex Capsules (Celecoxib): Medical Officer Review. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf. Accessed June 16, 2003.
Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.
JAMA. 2003;290:36.
RELATED ARTICLES
Pain Management in Patients With Osteoarthritis
Barry Egener
JAMA. 2003;290(1):36.
EXTRACT
| FULL TEXT
Pain Management in Patients With OsteoarthritisReply
Jess H. Lonner
JAMA. 2003;290(1):36.
EXTRACT
| FULL TEXT
|